AngioDynamics Announces Conference Call for Second Quarter FY08 Financial Results

AngioDynamics Announces Conference Call for Second Quarter FY08 Financial Results

QUEENSBURY, N.Y., Dec 20, 2007 (BUSINESS WIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, announced today that it plans to report its second fiscal quarter financial results on Thursday, January 3, 2008, after the close of the financial markets.

Eamonn P. Hobbs, president and chief executive officer, and Joseph Gersuk, executive vice president and CFO, will host an investment community conference call beginning at 4:30 p.m. Eastern time on January 3rd to discuss these results and to answer questions.

To participate in the live call by telephone, please dial (800) 218-0204 from the U.S., or for international callers, please dial (303) 262-2142.

Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of AngioDynamics' website at http://investor.angiodynamics.com. To listen to the live call, please go to the website 15 minutes prior to its start to register, download, and install the necessary audio software.

A replay will be available on the website. A telephone replay will be available from 7:30 p.m. Eastern time on January 3, 2008 through 11:59 p.m. Eastern time on January 11 by dialing (800) 405-2236 (domestic) or (303) 590-3000 (international) and entering the passcode: 11104157#.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products.

SOURCE: AngioDynamics, Inc.

AngioDynamics, Inc.
Company Contact:
D. Joseph Gersuk, 800-772-6446 ext. 1608 (CFO)
jgersuk@AngioDynamics.com
or
EVC Group, Inc.


Investor Relations Contacts:
Julie Huang/Doug Sherk, 646-443-6963
jhuang@evcgroup.com
dsherk@evcgroup.com
Media Contact:
Steve DiMattia, 646-201-5445
sdimattia@evcgroup.com